Volume 22, Issue 1 p. 45-51

Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications

Krishnaswamy Yeleswaram

Corresponding Author

Krishnaswamy Yeleswaram

Department of Metabolism & Pharmacokinetics

Address reprint requests to K. Yeleswaram, Ph.D., Bristol-Myers Squibb PRI, Dept. 904, 5 Research Parkway, Wallingford, CT 06492.Search for more papers by this author
Lee G. McLaughlin

Lee G. McLaughlin

Department of Metabolism & Pharmacokinetics

Search for more papers by this author
Jay O. Knipe

Jay O. Knipe

Department of Metabolism & Pharmacokinetics

Search for more papers by this author
David Schabdach

David Schabdach

Department of Veterinary Sciences, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut 06492

Search for more papers by this author
First published: 30 January 2007
Citations: 127

Abstract

Yeleswaram K, McLaughlin LG, Knipe JO, Schabdach D. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J. Pineal Res. 1997; 22:45–51. © Munksgaard, Copenhagen

A review of the literature indicates that the absolute oral bioavailability of exogenous melatonin in humans or in preclinical animal models has not been adequately characterized; hence, this study was undertaken. Pharmacokinetics of melatonin was studied in rats, dogs, and monkeys following intravenous and oral administrations, and the absolute oral bioavailability of melatonin was calculated from the area under the plasma concentration-time curve. The apparent elimination half-life of melatonin following an intravenous dose of 3 mg/kg (5 mg/kg in rats) was 19.8, 18.6, and 34.2 minutes, respectively, in rats, dogs, and monkeys. The dose normalized oral bioavailability of melatonin following a 10 mg/kg oral dose was 53.5% in rats, while it was in excess of 100% in dogs and monkeys. Further, bioavailability of melatonin following a 10 mg/kg intraperitoneal administration in rats was 74.0%, suggesting the lack of substantial first-pass hepatic extraction of melatonin in rats. However, the oral bioavailability of melatonin in dogs decreased to 16.9% following a 1 mg/kg oral dose, indicating dose-dependent bioavailability in dogs. In vitro permeability studies with CACO-2 cells suggest that melatonin is likely to be well absorbed in humans. In vitro metabolism studies with fresh liver slices from rats as well as human donors were conducted to compare the initial rates of metabolism of melatonin between the two species and the results suggest that the intrinsic clearance of melatonin in humans may be lower than that in rats.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.